google-site-verification: googlec7193c3de77668c9.html

Tirzepatide noninferior to dulaglutide for CV outcomes in type 2 diabetes

[
Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic CV disease, according to a study published in the Dec. 18/25 issue of the New England Journal of Medicine.


Source link

Advertisements

See also  Supervised physical exercise can improve the well-being of caregivers of the elderly

Check Also

Mitochondrial DNA levels reveal links to tumor growth and chemotherapy-related gene activity

[ Credit: Unsplash/CC0 Public Domain Mitochondria are small organelles within cells that play a central …

New guidelines warn against obesity drugs for young children

Estimates suggest 170 million children and adolescents worldwide are obese. That includes 70 million children …

Hampshire woman calls for medically-advised abortion awareness

A woman whose baby was too ill to be born is calling for better awareness …

Leave a Reply

Available for Amazon Prime